(Q33881113)

29 July 2017

1 reference

title

Prediction of deterioration in mild cognitive disorder in old age--neuropsychological and neurochemical parameters of dementia diseases (English)

1 reference

29 July 2017

1 reference

1 reference

1 reference

Reischies FM

1

1 reference

PubMed ID

10746907

29 July 2017

Hellweg R

series ordinal

2

1 reference

29 July 2017

1 March 2000

1 reference

29 July 2017

Comprehensive Psychiatry

1 reference

29 July 2017

41

1 reference

29 July 2017

2 Suppl 1

1 reference

29 July 2017

66-75

1 reference

Prevalence of dementia in old age: clinical diagnoses in subjects aged 95 years and older

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2800%2980011-5

Predictive features in mild senile dementia of the Alzheimer type

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2800%2980011-5

Incidence of dementia in a population older than 75 years in the United Kingdom.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2800%2980011-5

A prospective study of cognitive function in the elderly.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2800%2980011-5

ICD-10 mild cognitive disorder: epidemiological evidence on its validity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2800%2980011-5

[Normal and pathological cognitive aging]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2800%2980011-5

Linguistic ability in early life and cognitive function and Alzheimer's disease in late life. Findings from the Nun Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2800%2980011-5

Intelligence in schizophrenia: meta-analysis of the research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2800%2980011-5

A typology of sub-clinical senescent cognitive disorder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2800%2980011-5

Age and dementia effect on neuropsychological test performance in very old age--influence of risk factors for dementia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2800%2980011-5

In an epidemiological sample the apolipoprotein E4 allele is associated to dementia and loss of memory function only in the very old.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2800%2980011-5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2800%2980011-5

The epidemiology of dementia: GMS-AGECAT studies of prevalence and incidence, including studies in progress

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2800%2980011-5

Screening for dementia by memory testing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2800%2980011-5

Normal ageing, impaired cognitive function, and senile dementia of the Alzheimer's type: a continuum?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2800%2980011-5

Normal ageing, impaired cognitive functioning and senile dementia--a mixture distribution analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2800%2980011-5

Education and the prevalence of dementia and Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2800%2980011-5

Specific hippocampal volume reductions in individuals at risk for Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2800%2980011-5

Excitotoxicity, free radicals, and cell membrane changes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2800%2980011-5

Neurotrophic factors in memory disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2800%2980011-5

Consensus Report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease” 11The names of the Working Group Members and the names of the Working Group Advisory Committee Members are listed in the Appendix A(section VI)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2800%2980011-5

Biological markers for the diagnosis of Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2800%2980011-5

Combination of the different biological markers for increasing specificity of in vivo Alzheimer's testing.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2800%2980011-5

High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2800%2980011-5

Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2800%2980011-5

Combination assay of CSF tau, A beta 1-40 and A beta 1-42(43) as a biochemical marker of Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2800%2980011-5

Tau Protein in Cerebrospinal Fluid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2800%2980011-5

Cerebrospinal protein tau is elevated in early Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2800%2980011-5

Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2800%2980011-5

Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2800%2980011-5

Apolipoprotein E genotyping and cerebrospinal fluid tau protein: implications for the clinical diagnosis of Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2800%2980011-5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2800%2980011-5

Interleukin-6 (IL-6) and soluble forms of IL-6 receptors are not altered in cerebrospinal fluid of Alzheimer's disease patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2800%2980011-5

Cerebrospinal fluid microglial antibodies: potential diagnostic markers for immune mechanisms in Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2800%2980011-5

Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2800%2980011-5

Cerebrospinal fluid levels of amyloid precursor protein and amyloid beta-peptide in Alzheimer's disease and major depression - inverse correlation with dementia severity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2800%2980011-5

Amyloid beta protein in plasma from patients with sporadic Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2800%2980011-5

CSF neurotransmitter markers in Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2800%2980011-5

Choline levels are increased in cerebrospinal fluid of Alzheimer patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2800%2980011-5

Neurotransmitter amino acids in cerebrospinal fluid of patients with Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2800%2980011-5

The time course of nerve growth factor content in different neuropsychiatric diseases--a unifying hypothesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2800%2980011-5

NGF level in the rat sciatic nerve is decreased after long-term consumption of ethanol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2800%2980011-5

Endogenous levels of nerve growth factor (NGF) are altered in experimental diabetes mellitus: a possible role for NGF in the pathogenesis of diabetic neuropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2800%2980011-5

Axonal transport of endogenous nerve growth factor (NGF) and NGF receptor in experimental diabetic neuropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2800%2980011-5

The role of endogenous nerve growth factor in human diabetic neuropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2800%2980011-5

NGF content in the cerebral cortex of non-demented patients with amyloid-plaques and in symptomatic Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2800%2980011-5

Insights into the role of the cholinergic component of the septohippocampal pathway: what have we learned from experimental lesion studies?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2800%2980011-5

Nerve growth factor levels and choline acetyltransferase activity in the brain of aged rats with spatial memory impairments.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2800%2980011-5

Moderate lesion of the rat cholinergic septohippocampal pathway increases hippocampal nerve growth factor synthesis: evidence for long-term compensatory changes?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2800%2980011-5

Two-site enzyme immunoassay for beta NGF applied to human patient sera

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2800%2980011-5

NGF level of is not decreased in the serum, brain-spinal fluid, hippocampus, or parietal cortex of individuals with Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2800%2980011-5

Anti-NGF autoantibodies and NGF in sera of Alzheimer patients and in normal subjects in relation to age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2800%2980011-5

Increased levels of truncated nerve growth factor receptor in urine of mildly demented patients with Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2800%2980011-5

Nerve growth factor: from neurotrophin to neurokine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2800%2980011-5

Cerebrospinal fluid markers of Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-440X%2800%2980011-5

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0010-440X(00)80011-5

1 reference

29 July 2017

1 reference

PubMed ID

10746907